through wyeth australia, wyeth manufactures and sells its extended release formulation of venlafaxine hydrochloride under the name efexor-xr .
the respondents are (respectively) an innovator pharmaceutical company incorporated in the united state of america, wyeth, and its wholly owned australian subsidiary, wyeth australia pty limited ( wyeth and wyeth australia ).
associate: dated: 25 august 2009 counsel for the applicant/cross-respondent: mr s c g burley sc and mr p w flynn counsel for the first and second respondents/cross-claimants: mr a j l bannon sc, mr b n caine sc and mr c dimitriadis solicitor for the applicant/cross-respondent mallesons stephen jaques solicitor for the first and second respondents/cross-claimants: gilbert + tobin date of hearing: 14 august 2009 date of judgment: 25 august 2009 austlii: copyright policy | disclaimers | privacy policy | feedback url: http://www.austlii.edu.au/au/cases/cth/fca/2009/945.html